Aquestive Therapeutics (NASDAQ:AQST) Trading Down 4.4% - Should You Sell?

Aquestive Therapeutics, Inc. (NASDAQ:AQST - Get Free Report) was down 4.4% during mid-day trading on Thursday . The stock traded as low as $5.18 and last traded at $5.1550. Approximately 837,966 shares were traded during mid-day trading, a decline of 73% from the average session volume of 3,103,022 shares. The stock had previously closed at $5.39.

Trending Headlines about Aquestive Therapeutics

Here are the key news stories impacting Aquestive Therapeutics this week:

• Positive Sentiment: HC Wainwright reiterated its “Buy” rating and $10 price target, implying substantial upside relative to the stock’s recent trading level. HC Wainwright Reiterates Buy Rating for Aquestive Therapeutics
• Positive Sentiment: HC Wainwright raised its earnings estimates across multiple periods. The firm improved its forecast for Q3 2026 EPS to a $0.09 loss from a $0.13 loss, Q4 2026 EPS to a $0.09 loss from $0.15, and FY2026 EPS to a $0.43 loss from $0.51. It also raised FY2027 EPS to a $0.39 loss from $0.52, with smaller upgrades for Q1, Q2 and Q4 2027. These revisions suggest expectations for improving financial performance and narrowing losses.
• Neutral Sentiment: The revised forecasts still show ongoing losses. HC Wainwright expects AQST to remain unprofitable through 2027, while the broader consensus calls for a $0.50 loss per share in the current year. The estimates are more optimistic but do not yet indicate a transition to profitability.
• Neutral Sentiment: Short-interest data appears unreliable. The report lists short interest at zero shares both before and after the period, along with a “NaN” percentage change and zero days to cover. Consequently, it provides no meaningful evidence of short-covering or short-selling pressure.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on AQST. Weiss Ratings reissued a "sell (d-)" rating on shares of Aquestive Therapeutics in a research report on Friday, July 17th. Wall Street Zen cut Aquestive Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday, August 15th. Finally, HC Wainwright reiterated a "buy" rating and set a $10.00 target price on shares of Aquestive Therapeutics in a research note on Monday. Two analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, Aquestive Therapeutics presently has a consensus rating of "Buy" and an average price target of $8.80.

Aquestive Therapeutics Stock Performance

The firm has a market cap of $654.55 million, a PE ratio of -8.02 and a beta of 1.49. The stock has a 50-day simple moving average of $4.23 and a two-hundred day simple moving average of $4.15.

Aquestive Therapeutics (NASDAQ:AQST - Get Free Report) last announced its quarterly earnings results on Tuesday, August 11th. The company reported ($0.18) EPS for the quarter, missing analysts' consensus estimates of ($0.10) by ($0.08). The firm had revenue of $13.82 million for the quarter, compared to analysts' expectations of $11.42 million. As a group, sell-side analysts anticipate that Aquestive Therapeutics, Inc. will post -0.5 EPS for the current fiscal year.

Insider Transactions at Aquestive Therapeutics

In other Aquestive Therapeutics news, Director Julie Krop sold 25,000 shares of Aquestive Therapeutics stock in a transaction that occurred on Tuesday, June 23rd. The shares were sold at an average price of $5.02, for a total value of $125,500.00. Following the completion of the sale, the director owned 25,000 shares of the company's stock, valued at approximately $125,500. The trade was a 50.00% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 6.81% of the company's stock.

Hedge Funds Weigh In On Aquestive Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the company. NewEdge Advisors LLC bought a new stake in shares of Aquestive Therapeutics in the third quarter worth $28,000. BNP Paribas Financial Markets lifted its holdings in Aquestive Therapeutics by 78.3% in the second quarter. BNP Paribas Financial Markets now owns 9,413 shares of the company's stock valued at $31,000 after acquiring an additional 4,134 shares during the period. ADAR1 Capital Management LLC boosted its position in Aquestive Therapeutics by 103.9% in the first quarter. ADAR1 Capital Management LLC now owns 10,000 shares of the company's stock worth $42,000 after purchasing an additional 264,000 shares during the last quarter. Modern Wealth Management LLC purchased a new position in Aquestive Therapeutics in the second quarter worth about $33,000. Finally, Elevation Point Wealth Partners LLC bought a new stake in shares of Aquestive Therapeutics during the 1st quarter valued at about $42,000. 32.45% of the stock is owned by institutional investors.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc is a specialty pharmaceutical company focused on the development and commercialization of novel drug delivery systems. Leveraging its proprietary PharmFilm® technology, Aquestive designs thin-film formulations that facilitate sublingual, buccal and oral delivery of small molecules, offering rapid onset of action and improved patient compliance compared with traditional dosage forms.

The company's lead product, Libervant® (diazepam) Buccal Film, is approved by the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source